According to Omnicell 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -193.474. At the end of 2021 the company had a P/E ratio of 101.
Year | P/E ratio | Change |
---|---|---|
2021 | 101 | -35.33% |
2020 | 156 | 182.29% |
2019 | 55.2 | -13.44% |
2018 | 63.8 | -28.97% |
2017 | 89.8 | -96.21% |
2016 | > 1000 | 6461.95% |
2015 | 36.1 | -6.16% |
2014 | 38.5 | 2.58% |
2013 | 37.5 | 23.72% |
2012 | 30.3 | -41.22% |
2011 | 51.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Cerner CERN | 47.5 | -124.53% | ๐บ๐ธ USA |
![]() AmerisourceBergen
ABC | 22.4 | -111.59% | ๐บ๐ธ USA |
![]() Cardinal Health CAH | 48.2 | -124.92% | ๐บ๐ธ USA |
![]() McKesson MCK | 17.7 | -109.14% | ๐บ๐ธ USA |
![]() Steris STE | -736 | 280.65% | ๐ฎ๐ช Ireland |
![]() Premier PINC | 16.8 | -108.70% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.